UPDATE 1-Bristol-Myers lung cancer delay slams shares, keeps Merck in lead

New YORK, Jan 20 (Reuters) - Bristol-Myers Squibb Coshares fell 11 percent on Friday following Thursday's
announcement that it would not seek accelerated approval of its
immunotherapy drug...